CN115057804A - Purification method of calcitriol - Google Patents
Purification method of calcitriol Download PDFInfo
- Publication number
- CN115057804A CN115057804A CN202210592338.5A CN202210592338A CN115057804A CN 115057804 A CN115057804 A CN 115057804A CN 202210592338 A CN202210592338 A CN 202210592338A CN 115057804 A CN115057804 A CN 115057804A
- Authority
- CN
- China
- Prior art keywords
- calcitriol
- ethyl acetate
- hexane
- tbs
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000020964 calcitriol Nutrition 0.000 title claims abstract description 87
- 239000011612 calcitriol Substances 0.000 title claims abstract description 87
- 229960005084 calcitriol Drugs 0.000 title claims abstract description 86
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 46
- 238000000746 purification Methods 0.000 title claims abstract description 26
- 238000000855 fermentation Methods 0.000 claims abstract description 30
- 230000004151 fermentation Effects 0.000 claims abstract description 30
- 239000012043 crude product Substances 0.000 claims abstract description 22
- 239000000047 product Substances 0.000 claims abstract description 19
- 238000000926 separation method Methods 0.000 claims abstract description 13
- 230000000813 microbial effect Effects 0.000 claims abstract description 12
- 238000007670 refining Methods 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 111
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 55
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 239000012535 impurity Substances 0.000 claims description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 22
- 239000003480 eluent Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 16
- 239000012044 organic layer Substances 0.000 claims description 16
- 238000004440 column chromatography Methods 0.000 claims description 15
- 239000000758 substrate Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 13
- 238000004821 distillation Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000012544 monitoring process Methods 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 239000010410 layer Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 9
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims description 9
- 229960002535 alfacalcidol Drugs 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 230000001012 protector Effects 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims description 6
- 241000187603 Pseudonocardia Species 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 239000012065 filter cake Substances 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012074 organic phase Substances 0.000 claims description 3
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000010511 deprotection reaction Methods 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 238000011068 loading method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- GMRQFYUYWCNGIN-DRQJEBLXSA-N (1r,3s,5e)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-DRQJEBLXSA-N 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000869142 Pseudonocardia sp. Species 0.000 description 1
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000003553 hypophosphatemic effect Effects 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 201000003868 postsurgical hypothyroidism Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 229940106904 rocaltrol Drugs 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 208000032349 type 2B vitamin D-dependent rickets Diseases 0.000 description 1
- 208000030402 vitamin D-dependent rickets Diseases 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to a method for purifying calcitriol. The calcitriol preparation method is characterized in that fermentation liquor containing a calcitriol crude product prepared by microbial fermentation is subjected to separation and purification, TBS protection, deprotection, refining and purification, the production process is mature, the conditions are mild, and the method is suitable for industrial production. The purity of the calcitriol pure product prepared by the method is more than 98%, preferably more than 99%, and most preferably more than 99.8%.
Description
Technical Field
The invention belongs to the technical field of chemical pharmacy, and particularly relates to a purification method of calcitriol.
Background
Calcitriol (Calcitriol) with the chemical name: 1, 25-dihydroxycholecalciferol or 1, 25-dihydroxyvitamin D 3 The structural formula is as follows:
calcitriol is a metabolite of vitamin D3 which is metabolized by liver and kidney hydroxylase to be the most active in resisting rickets. Can promote the absorption of calcium in intestinal tract and regulate the calcification of bone. Calcitriol was first produced by roche, switzerland, marketed in 1978 under the trade designation "Rocaltrol", and was used for the treatment of postmenopausal osteoporosis, chronic renal dysfunction, postoperative hypothyroidism, idiopathic parathyroidism, pseudohypothyroidism, vitamin D-dependent rickets, hypophosphatemic vitamin D-resistant rickets, and the like. Because calcitriol is an endogenous substance, the curative effect is definite, and the calcitriol is safe and stable, the calcitriol is the first choice medicine for osteoporosis.
Calcitriol has high physiological activity, and the dosage of the calcitriol taken at a single time is very small, and the common treatment dosage is only 0.25 mu g/day to 1.0 mu g/day. Calcitriol is unstable in property, sensitive to light and heat, contains a plurality of chiral centers, is long in the traditional photochemical synthesis route, inevitably generates isomer impurities and other related substances easily in the synthesis process, and is difficult to separate and purify, so that the synthesis process technology threshold is high and the difficulty is high.
The preparation process of the calcitriol is different from the traditional photochemical synthesis method and is prepared by adopting a microbial fermentation method, two extremely high impurities PZA and PZB are unexpectedly found in the process of extracting and purifying fermentation liquor, the total content of the two extremely high impurities is more than 10%, the polar position of the impurity is found to be close to that of the calcitriol by a thin-layer point plate, and the two extremely high impurities are difficult to remove by adopting purification methods such as column chromatography, DAC dynamic preparation and the like, so that higher difficulty is brought to the purification work of final products.
Disclosure of Invention
In order to solve the problems, the invention provides a method for purifying calcitriol, which is obtained by separating and purifying fermentation liquor containing a calcitriol crude product obtained by microbial fermentation, TBS protection, deprotection, refining and purification, has mature production process and mild conditions, and is suitable for industrial production.
The technical scheme for realizing the invention is as follows:
the invention provides a purification method of calcitriol, which comprises the following steps:
(1) the fermentation process comprises the following steps: taking alfacalcidol as a starting material, converting the alfacalcidol into calcitriol through one-step microbial fermentation, centrifuging the obtained fermentation liquor to remove fungus residues, and collecting supernatant;
(2) and (3) crude product extraction and purification: extracting the fermented supernatant by using an organic solvent, collecting an organic phase, and separating by using column chromatography to obtain a calcitriol crude product 1;
(3) TBS protection of hydroxyl groups: introducing a protecting group TBS into hydroxyl groups at 1 and 3 positions of a calcitriol crude product 1, and separating by column chromatography to obtain a calcitriol TBS protecting substance;
(4) TBS removal: and (3) carrying out TBS removal protection on the TBS protection substance of calcitriol, carrying out column chromatography separation, crystallizing and filtering to obtain the calcitriol.
In some embodiments, the microbial fermentation conversion method in step (1) is to perform fermentation culture and centrifugal separation on the Pseudonocardia HRW001 to obtain the thallus of the Pseudonocardia HRW001, and apply the thallus to the starting material alfacalcidol for microbial conversion.
In some embodiments, the specific method for extracting the crude product in step (2) is as follows: transferring the fermentation supernatant into a reaction kettle, adding ethyl acetate, stirring, standing for 3-5 min, separating liquid, collecting an organic layer, introducing a water layer into the reaction kettle, adding ethyl acetate, stirring, standing for 3-5 min, separating liquid, collecting the organic layer, removing the water layer, combining the organic layers, stirring and drying with anhydrous sodium sulfate, filtering, concentrating the filtrate at 40-50 ℃ under reduced pressure until the filtrate is dry, and dissolving a distillation substrate with n-hexane at 40-50 ℃ under normal pressure for later use.
In some embodiments, the eluent used for column chromatography separation in step (2) is ethyl acetate-n-hexane solution by the following specific method: eluting with n-hexane/ethyl acetate (5/1), changing to the n-hexane/ethyl acetate (1/1) to elute the main product, monitoring by TLC, and after elution is finished, concentrating the main point eluent at 40-50 ℃ under reduced pressure to obtain a calcitriol crude product 1.
In some embodiments, the specific method for protecting hydroxyl groups with TBS in step (3) is: dissolving TBSCl in tetrahydrofuran for later use, dissolving a calcitriol crude product 1 in tetrahydrofuran, putting the mixture into a reaction bottle, adding imidazole, controlling the temperature to be below 30 ℃, dropwise adding a TBSCl tetrahydrofuran solution for later use, keeping the temperature to be 25 +/-5 ℃ for reaction for 2-3 h, monitoring the reaction by TLC, after the reaction is completed, adding purified water, stirring, standing, layering, collecting an organic layer, stirring and drying with anhydrous sodium sulfate, filtering, concentrating the filtrate at 40-50 ℃ under reduced pressure until the filtrate is dry, and dissolving a distillation substrate in normal pressure at 40-50 ℃ with normal hexane for later use.
In some embodiments, the eluent used for column chromatography separation in step (3) is ethyl acetate-n-hexane solution by the following specific method: eluting the precursor impurities by using normal hexane/ethyl acetate (100/1), then eluting the main product by using normal hexane/ethyl acetate (1/1), monitoring by using TLC (thin layer chromatography), and after the elution is finished, concentrating the main point eluent at 40-50 ℃ under reduced pressure to obtain the calcitriol TBS protective substance.
In some embodiments, in the step (4), the calcitriol TBS protective substance is dissolved in tetrahydrofuran and transferred to a reaction flask, 1M TBAF-THF is added, nitrogen is replaced three times and protected, the temperature is raised to 50-60 ℃ for reaction for 3-4 h, TLC monitors the reaction, purified water is added after the reaction is completed, the mixture is stirred, the mixture is stood still and layered, an organic layer is collected, the mixture is stirred and dried with anhydrous sodium sulfate, the filtrate is filtered, the filtrate is concentrated to dryness at 40-50 ℃ under reduced pressure, and a distillation substrate is dissolved in normal pressure at 40-50 ℃ by normal hexane for standby.
In some embodiments, the eluent used for column chromatography separation in step (4) is ethyl acetate-n-hexane solution by the following specific method: eluting with normal hexane/ethyl acetate (5/1), eluting a main product with normal hexane/ethyl acetate (1/1), monitoring by TLC (thin layer chromatography), concentrating the main point eluent at 40-50 ℃ under reduced pressure, dissolving a distillation substrate with 3-5 times of ethyl acetate at 40 ℃, dropwise adding 3-5 times of ethyl acetate, heating to 50 +/-5 ℃, slowly cooling to room temperature, cooling to 0 +/-5 ℃, stirring, crystallizing for 0.5-3 h, filtering, and drying a filter cake to obtain calcitriol.
In some embodiments, the method comprises a further refining process, specifically, dissolving calcitriol prepared in the step (4) in ethyl formate, heating to 40-50 ℃ for dissolving under the protection of nitrogen, slowly cooling to room temperature, then cooling to-20 +/-5 ℃, stirring for crystallization for 2-3 hours, heating, cooling, crystallizing and filtering to obtain a pure calcitriol product.
The purity of the calcitriol purified by the method is more than 98%, preferably more than 99%, and most preferably more than 99.8%.
Drawings
FIG. 1 is a HPLC chromatogram for detecting related substances in fermentation supernatant.
FIG. 2 is a HPLC chromatogram for detecting related substances in crude calcitriol 1.
FIG. 3 is a HPLC chromatogram for detecting related substances in the crude calcitriol 2.
FIG. 4 is HPLC chromatogram for detecting related substances of calcitriol pure product.
Detailed Description
The present invention will be described in further detail with reference to the following examples and figures, which are illustrative only and not intended to be limiting, and the scope of the present invention is not limited thereto, and the materials used are commercially available or may be obtained by the self-made method unless otherwise specified.
EXAMPLE 1 Synthesis (fermentation Process) of calcitriol crude 1
The calcitriol is prepared by a microbial fermentation method, and the specific preparation method refers to the following patent publication numbers: CN110527650A, obtained by the method described in examples 1-5, using alfacalcidol as a starting material, and converting the alfacalcidol into a calcitriol crude product through one-step microbial fermentation. Pseudonocardia HRW001 for microbial fermentation. Identified by China general microbiological culture Collection center, the strain is classified and named as Pseudonocardia Pseudonocardia sp.HRW001, the strain is preserved in the China general microbiological culture Collection center in 2019 at 03.04.17524, and the preservation number is CGMCC No. 17524. HPLC detection results of fermentation supernatant related substances after the fermentation broth is subjected to centrifugal separation are shown in table 1, corresponding to figure 1.
TABLE 1
Calcitriol producens | Impurity PY1 | Calcitriol | Impurity PZA | Impurity PZB | Alfacalcidol | |
Time to peak min | 17.430 | 18.870 | 19.913 | 23.753 | 26.153 | 32.513 |
Peak area ratio% | 2.48 | 0.64 | 72.75 | 4.31 | 7.82 | 2.00 |
The above results show that, in the process of extraction and purification of fermentation liquor, besides the impurity preosteviol and the impurity PY1 (trans-calcitriol) of the traditional process, two impurities PZA and PZB with extremely high content are also discovered unexpectedly, and the total content is more than 10%.
The two impurities are obtained by derivatization, separation and purification, and the structural formula and the nomenclature are as follows after the structure confirmation:
impurity PZA:
chinese culture name: (5Z,7E) -9, 10-Ring-opened cholest-5, 7,10(19) -triene-1 alpha, 3 beta, 26-triol
Chemical structural formula:
impurity PZB:
chinese culture name: (5Z,7E) -9, 10-Ring-opened cholest-5, 7,10(19) -triene-1 alpha, 3 beta, 24-triol
Chemical structural formula:
EXAMPLE 2 extraction and purification of crude calcitriol 1
Transferring 160L (calculated by 90g of substrate) of the centrifuged fermentation liquor into a 500L reaction kettle, adding 25L of ethyl acetate, stirring for 3-5 min, standing for 3-5 min, separating liquid, collecting an organic layer, introducing a water layer into the reaction kettle, adding 25L of ethyl acetate, stirring for 3-5 min, standing for 3-5 min, separating liquid, collecting the organic layer, and removing the water layer. And combining the two organic layers, drying the organic layer by using 1.8kg of anhydrous sodium sulfate, filtering, concentrating the filtrate at 40-50 ℃ under reduced pressure until the filtrate is dry, and adding 0.45L of n-hexane into the distillation substrate to dissolve the distillation substrate at 40 ℃ under normal pressure for later use.
Preparing a column with the diameter of 12cm and the height of about 120cm, weighing 1.8kg of 100-200-mesh silica gel, loading a standby n-hexane dissolving solution into the column at normal pressure, using 8.0-9.0L of n-hexane/ethyl acetate 5/1 for eluting the precursor impurity, using n-hexane/ethyl acetate 1/1 for eluting a main product, monitoring by TLC (a developing agent: n-hexane/ethyl acetate 1/2, a color development method: ultraviolet 254nm + phosphomolybdic acid heating), after the elution is finished, concentrating the main point eluent at 40-50 ℃ under reduced pressure, and drying to obtain 57.0g of oily matter, namely calcitriol crude product 1(GC-C1).
The HPLC detection results of related substances of the calcitriol crude product 1 are shown in Table 2 and correspond to the attached figure 2.
TABLE 2
Calcitriol producens | Impurity PY1 | Calcitriol | Impurity PZA | Impurity PZB | |
Time to peak min | 17.430 | 18.647 | 19.890 | 23.733 | 26.147 |
Peak area ratio% | 1.14 | 0.47 | 89.56 | 4.7 | 1.6 |
The results show that the calcitriol crude product obtained by extracting and purifying the fermentation liquor by silica gel column chromatography still contains high-content impurities PZA and PZB, and the impurities cannot be effectively removed by the traditional purification mode.
From the structural comparison of the two impurities PZA and PZB with calcitriol, it is not difficult to find the difference of the main structural difference in the position of the side chain introduced hydroxyl group, wherein, the hydroxyl at the 26 and 24 positions of the side chains of the impurities PZA and PZB is easy to introduce TBS protecting groups, and the steric hindrance of 25-hydroxyl of calcitriol is large, and TBS protecting groups are difficult to introduce, so that a crude product obtained after fermentation, by introducing TBS protecting group, only 1, 3-hydroxy is protected by TBS by calcitriol, and three hydroxyls of the impurities PZA and PZB can be protected by TBS, so that the impurities PZA and PZB can be separated by column chromatography through the difference of the polarity of the three after the TBS protection, the hydroxylTBS protectors of the impurities PZA and PZB can be directly removed, the purpose of separating and removing the impurities PZA and PZB can be indirectly achieved, and the obtained calcitriol 1 and 3-position hydroxylTBS protectors are subjected to TBS removal protection, column chromatography purification and recrystallization to obtain the calcitriol with higher purity.
EXAMPLE 3 calcitriol 1, 3-dihydroxy TBS protection
The reaction formula is as follows:
weighing 92.9g of TBSCl, dissolving in 114ml of tetrahydrofuran for later use, dissolving the crude product 1 in 570ml of tetrahydrofuran at room temperature, putting into a 2.0L three-mouth reaction bottle, adding 83.8g of imidazole, dropwise adding a TBSCl THF solution for later use at the temperature of below 30 ℃, keeping the temperature for 2-3 h at 25 +/-5 ℃, reacting for 2-3 h, monitoring the reaction by TLC, adding 285ml of purified water after the reaction is completed, stirring for 3-5 min, standing for 3-5 min, layering, collecting an organic layer, stirring and extracting a water layer with 285ml of ethyl acetate for 3-5 min, standing for 3-5 min, layering, discarding the water layer, combining the organic layers, stirring and drying with 171g of anhydrous sodium sulfate, filtering, concentrating the filtrate at 40-50 ℃ under reduced pressure until no liquid drops drop occurs, concentrating for 10-20 min again to obtain a light yellow substance, and dissolving in 513ml of n-hexane at 40 ℃ under normal pressure for later use.
Preparing a column with the diameter of 12cm and the height of about 120cm, weighing 1.8kg of 100-200-mesh silica gel, loading an n-hexane solution in which oily substances are dissolved into the column at normal pressure, eluting with n-hexane/ethyl acetate (100/1), eluting after the loading is finished (thin layer development is adopted, developing agent: n-hexane/ethyl acetate (10/1)), eluting main product points with the n-hexane/ethyl acetate (1/1), and concentrating the main point eluent at 40-50 ℃ under reduced pressure to obtain 70g of calcitriol TBS protector.
EXAMPLE 4 preparation of crude calcitriol 2
The reaction formula is as follows:
dissolving 70g of calcitriol TBS protector by 700ml of tetrahydrofuran, transferring the dissolved calcitriol TBS protector into a 2.0L three-mouth reaction bottle, adding 553ml of 1M TBAF-THF, replacing nitrogen for three times and protecting, heating to 50-60 ℃ for reaction for 3-4 h, monitoring by TLC, after the reaction is completed, concentrating to be dry at 40-50 ℃ under reduced pressure, adding 700ml of ethyl acetate and 700ml of purified water into a distillation substrate, stirring for 5-10 min, standing for 3-5 min, layering, discarding a water layer, adding 140g of anhydrous sodium sulfate into an organic phase, stirring and drying for 30 +/-5 min, filtering, concentrating a filtrate at 40-50 ℃ under reduced pressure to be dry, and dissolving the distillation substrate by 350ml of ethyl acetate at 40-50 ℃ under normal pressure for later use.
Preparing a column with the diameter of 5cm and the height of about 150cm, weighing 700g of 100-200 mesh silica gel, loading a standby ethyl acetate solution into the column at normal pressure, using the column after loading, eluting the previous impurities with 8.0-9.0L of n-hexane/ethyl acetate (5/1), then using n-hexane/ethyl acetate (1/1) to elute a main product (eluent can be repeatedly used when the product does not appear), monitoring impurity points (a developing agent: n-hexane/ethyl acetate (1/2)) behind the main product through a thin layer during the process, heating and developing through phosphomolybdic acid, collecting main point eluent which is confirmed to be not crossed with the impurity points, then concentrating to be dry at 40-50 ℃ under reduced pressure, dissolving a distillation substrate at 40 ℃ by using ethyl acetate with the volume of 3-5 times of the weight of the distillation substrate, then dropwise adding n-hexane with the volume of 3-5 times of the ethyl acetate, heating to 50 ℃ and maintaining for 0.5h after dropwise adding, cooling to 0 ℃, crystallizing for 0.5h, filtering, drying a filter cake at 30-40 ℃ for 2h to obtain 25.80g of calcitriol crude product 2 (GC-C2).
The HPLC detection results of related substances of the calcitriol crude product 2 are shown in Table 3 and correspond to the attached figure 3.
TABLE 3
Calcitriol producens | Impurity PY1 | Calcitriol | Impurity PZB | |
Time to peak min | 17.457 | 18.847 | 19.940 | 26.193 |
Peak area ratio% | 0.46 | 0.17 | 99.22 | 0.04 |
EXAMPLE 5 calcitriol purification
Adding 25.80g of calcitriol crude product 2 and 516ml of ethyl formate into a 1000ml three-mouth reaction bottle, replacing nitrogen for three times and protecting, heating to 40-50 ℃ to dissolve, slowly cooling to room temperature, then cooling to-20 +/-5 ℃, stirring to crystallize for 2-3 h, filtering, and drying a filter cake in vacuum at 40-50 ℃ for 30-40 h to obtain 20.60g of calcitriol pure product (GC), wherein the yield is 79.84%.
The HPLC detection results of the related substances of the calcitriol refined product are shown in Table 4, corresponding to figure 4.
TABLE 4
Calcitriol producens | Impurity PY1 | Calcitriol | |
Time to peak min | 17.573 | 18.933 | 20.040 |
Peak area ratio% | 0.07 | 0.05 | 99.81 |
The above results show that the purified calcitriol has a purity as high as 99.81%, and two fermentation impurities PZA and PZB are effectively removed.
Claims (10)
1. A method for purifying calcitriol, which is characterized by comprising the following steps:
the fermentation process comprises the following steps: taking alfacalcidol as a starting material, converting the alfacalcidol into calcitriol through one-step microbial fermentation, centrifuging the obtained fermentation liquor to remove fungus residues, and collecting supernatant;
and (3) crude product extraction and purification: extracting the fermented supernatant by using an organic solvent, collecting an organic phase, and separating by using column chromatography to obtain a calcitriol crude product 1;
TBS protection of hydroxyl groups: introducing a protecting group TBS into hydroxyl groups at 1 and 3 positions of a calcitriol crude product 1, and separating by column chromatography to obtain a calcitriol TBS protecting substance;
TBS removal: and (3) carrying out TBS removal protection on the TBS protection substance of calcitriol, carrying out column chromatography separation, crystallizing and filtering to obtain the calcitriol.
2. The purification method according to claim 2, wherein the microbial fermentation conversion method in step (1) comprises subjecting the Pseudonocardia HRW001 to fermentation culture and centrifugal separation to obtain Pseudonocardia HRW001 cells, and applying the cells to the starting material alfacalcidol for microbial conversion.
3. The purification method according to claim 1, wherein the fermentation supernatant in the step (2) is transferred to a reaction kettle, ethyl acetate is added and stirred, the mixture is kept still for 3-5 min, the liquid is separated, the organic layer is collected, the water layer is introduced into the reaction kettle again, ethyl acetate is added and stirred, the mixture is kept still for 3-5 min, the liquid is separated, the organic layer is collected, the water layer is removed, the organic layers are combined, anhydrous sodium sulfate is used for stirring and drying, the filtration is carried out, the filtrate is concentrated to dryness under reduced pressure at 40-50 ℃, and the distillation substrate is dissolved by normal pressure by normal hexane at 40-50 ℃ for standby.
4. The purification method according to claim 1, wherein the eluent used in the column chromatography separation in step (2) is an ethyl acetate-n-hexane solution, and the specific method is as follows: eluting with n-hexane/ethyl acetate =5/1, then eluting with n-hexane/ethyl acetate =1/1 to obtain a main product, monitoring by TLC, and after elution is finished, concentrating the main point eluent at 40-50 ℃ under reduced pressure to obtain a calcitriol crude product 1.
5. The purification method of claim 1, wherein the TBS in step (3) protects hydroxyl groups by a specific method comprising: dissolving TBSCl in tetrahydrofuran for later use, dissolving a calcitriol crude product 1 in tetrahydrofuran, putting the solution into a reaction bottle, adding imidazole, dropwise adding a TBSCl tetrahydrofuran solution for later use at the temperature of below 30 ℃, keeping the temperature at 25 +/-5 ℃ for reaction for 2-3 h, monitoring the reaction by TLC, adding purified water after the reaction is completed, stirring, standing, layering, collecting an organic layer, stirring and drying with anhydrous sodium sulfate, filtering, concentrating the filtrate at 40-50 ℃ under reduced pressure to dryness, and dissolving a distillation substrate in normal pressure at 40-50 ℃ with normal hexane for later use.
6. The purification method according to claim 1, wherein the eluent used in the column chromatography separation in step (3) is an ethyl acetate-n-hexane solution, and the specific method is as follows: eluting the precursor impurities by using normal hexane/ethyl acetate =100/1, then eluting the main product by using normal hexane/ethyl acetate =1/1, monitoring by TLC, and after the elution is finished, concentrating the main point eluent at 40-50 ℃ under reduced pressure to obtain the calcitriol TBS protector.
7. The purification method as claimed in claim 1, wherein in the step (4), the calcitriol TBS protector is dissolved in tetrahydrofuran and transferred to a reaction bottle, 1M of TBAF-THF is added, nitrogen is replaced for three times and protected, the temperature is raised to 50-60 ℃ for reaction for 3-4 h, TLC is used for monitoring the reaction, after the reaction is completed, purified water is added, stirring is carried out, standing is carried out, layering is carried out, an organic layer is collected, anhydrous sodium sulfate is used for stirring and drying, filtering is carried out, the filtrate is concentrated to dryness under reduced pressure at 40-50 ℃, and a distilled substrate is dissolved in normal pressure at 40-50 ℃ by using normal hexane for standby.
8. The purification method according to claim 1, wherein the eluent used in the column chromatography separation in step (4) is an ethyl acetate-n-hexane solution, and the specific method is as follows: eluting with n-hexane/ethyl acetate =5/1, eluting a main product with n-hexane/ethyl acetate =1/1, monitoring by TLC, after elution is finished, concentrating the main point eluent at 40-50 ℃ under reduced pressure to dry, dissolving a distillation substrate with 3-5 times of ethyl acetate by weight at 40 ℃, dropwise adding 3-5 times of ethyl acetate by volume of n-hexane, after dropwise adding, heating to 50 +/-5 ℃, slowly cooling to room temperature, then cooling to 0 +/-5 ℃, stirring for crystallization for 0.5-3 h, filtering, and drying a filter cake to obtain calcitriol.
9. The purification method according to claim 1, wherein the method comprises a further refining process, and specifically comprises the steps of dissolving the calcitriol prepared in the step (4) in ethyl formate, heating to 40-50 ℃ for dissolution under the protection of nitrogen, slowly cooling to room temperature, then cooling to-20 +/-5 ℃, stirring for crystallization for 2-3 hours, heating for cooling, crystallizing and filtering to obtain a pure calcitriol product.
10. The purification method according to any one of claims 1 to 9, wherein the purity of the calcitriol pure product is greater than 98%, preferably greater than 99%, most preferably greater than 99.8%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210592338.5A CN115057804B (en) | 2022-05-27 | 2022-05-27 | Calcitriol purification method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210592338.5A CN115057804B (en) | 2022-05-27 | 2022-05-27 | Calcitriol purification method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115057804A true CN115057804A (en) | 2022-09-16 |
CN115057804B CN115057804B (en) | 2024-03-29 |
Family
ID=83198997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210592338.5A Active CN115057804B (en) | 2022-05-27 | 2022-05-27 | Calcitriol purification method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115057804B (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182393A (en) * | 1991-08-09 | 1993-01-26 | Hoffmann-La Roche Inc. | Process for precursors to calcitriol and related compounds |
JPH05186420A (en) * | 1992-01-09 | 1993-07-27 | Yuki Gosei Kogyo Co Ltd | Production of 1alpha,25-dihydroxycholecalciferol |
JPH0641058A (en) * | 1992-07-21 | 1994-02-15 | Asahi Chem Ind Co Ltd | New vitamin d derivatives containing residue on hydroxyl group at 25-position, their production and their use |
US20030022872A1 (en) * | 2000-02-28 | 2003-01-30 | Hiroaki Takayama | Vitamin d derivatives having substituents at the 2 alpha-position |
US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
CN101607931A (en) * | 2009-07-23 | 2009-12-23 | 青岛正大海尔制药有限公司 | A kind of preparation method of calcitriol |
CN102732571A (en) * | 2011-04-15 | 2012-10-17 | 上海医药工业研究院 | Fermentation medium for producing calcitriol, calcitriol fermentation conversion method and use of the fermentation medium |
CN103159656A (en) * | 2011-12-08 | 2013-06-19 | 成都国为医药科技有限公司 | Preparation method of calcitriol |
CN110885304A (en) * | 2018-09-07 | 2020-03-17 | 上海医药工业研究院 | Preparation method of deuterated calcitriol and intermediate thereof |
CN111518006A (en) * | 2020-05-26 | 2020-08-11 | 无锡贝塔医药科技有限公司 | Preparation method of 25-hydroxy vitamin D3 and 1 alpha, 25-dihydroxy vitamin D3 and isotope internal standard compound thereof |
-
2022
- 2022-05-27 CN CN202210592338.5A patent/CN115057804B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182393A (en) * | 1991-08-09 | 1993-01-26 | Hoffmann-La Roche Inc. | Process for precursors to calcitriol and related compounds |
JPH05186420A (en) * | 1992-01-09 | 1993-07-27 | Yuki Gosei Kogyo Co Ltd | Production of 1alpha,25-dihydroxycholecalciferol |
JPH0641058A (en) * | 1992-07-21 | 1994-02-15 | Asahi Chem Ind Co Ltd | New vitamin d derivatives containing residue on hydroxyl group at 25-position, their production and their use |
US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
US20030022872A1 (en) * | 2000-02-28 | 2003-01-30 | Hiroaki Takayama | Vitamin d derivatives having substituents at the 2 alpha-position |
CN101607931A (en) * | 2009-07-23 | 2009-12-23 | 青岛正大海尔制药有限公司 | A kind of preparation method of calcitriol |
CN102732571A (en) * | 2011-04-15 | 2012-10-17 | 上海医药工业研究院 | Fermentation medium for producing calcitriol, calcitriol fermentation conversion method and use of the fermentation medium |
CN103159656A (en) * | 2011-12-08 | 2013-06-19 | 成都国为医药科技有限公司 | Preparation method of calcitriol |
CN110885304A (en) * | 2018-09-07 | 2020-03-17 | 上海医药工业研究院 | Preparation method of deuterated calcitriol and intermediate thereof |
CN111518006A (en) * | 2020-05-26 | 2020-08-11 | 无锡贝塔医药科技有限公司 | Preparation method of 25-hydroxy vitamin D3 and 1 alpha, 25-dihydroxy vitamin D3 and isotope internal standard compound thereof |
Also Published As
Publication number | Publication date |
---|---|
CN115057804B (en) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104844620B (en) | A kind of isolation and purification method of rapamycin | |
JP6931930B2 (en) | Improved process for producing fucoxanthin and / or polysaccharides from microalgae | |
EP3489250A1 (en) | Crystal form of dapagliflozin intermediate and preparation method therefor | |
CN112321408B (en) | Device and method for extracting vitamin K2 from microbial fermentation broth | |
CN105131071B (en) | A kind of synthetic method of the Tosylhydrazone of 25 hydroxy cholesterol acetate 7 | |
GB2153829A (en) | Hydroxyvitamin d2 isomers | |
CN115057804B (en) | Calcitriol purification method | |
CN106432276A (en) | Cefazolin sodium compound prepared according to novel intelligent crystallization technology and preparation of cefazolin sodium compound | |
CN116970018B (en) | Ergosterol preparation and extraction method | |
CN115108955B (en) | Separation and purification method of calcitriol related impurity PZB | |
NO342269B1 (en) | Preparation and purification of mupirocin calcium | |
CN1470510A (en) | Epi-nutgall catechin gallic acid ester monomer purifying process | |
CN112661744B (en) | Purification method of esomeprazole sodium | |
CN115109802A (en) | Preparation method, detection method and application of impurity PZA related to calcitriol | |
CN118109522A (en) | Method for preparing paricalcitol by utilizing microbial fermentation | |
CN115637281A (en) | Method for preparing UDCA isomer of 3 beta, 7 beta-dihydroxy-5 alpha-H | |
CN115505622A (en) | Method for preparing UDCA isomer of 3 alpha, 7 beta-dihydroxy-5 alpha-H | |
CN115838363B (en) | Purification method of mycophenolic acid | |
CN113754526A (en) | High-purity coenzyme Q10 purification process | |
CN114478340A (en) | Method for improving raw material utilization rate and product yield of vitamin D3 | |
CN114057572B (en) | Method for simultaneously extracting shikimic acid and quinic acid from ginkgo leaf | |
CN106831811B (en) | A method of preparing high-content nimoctin | |
JP2008137982A (en) | Process for preparing high-purity crystalline maltitol powder | |
CN112390817B (en) | Method for salting out and extracting tacrolimus fermentation liquor | |
CN106632524A (en) | Method for preparing high-content mannose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |